Gioia Turitto, MD
Clinical Cardiac Electrophysiology · Lititz, PANPI 1871594887
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.2%), food and beverage and grants — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Biotronik Inc. at 36.2% of the total. Reporting peaked in 2019 at $18,638 and has fallen 64.4% since, to $6,644 in 2025.
Across 101 payments — averaging $311.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$11K
- E.r. Squibb & Sons, L.L.C.$7K
- Boston Scientific$5K
- Medtronic$3K
- Pfizer$3K
- Abbott$436
- plus $2K from 10 others
Across 58 payments — averaging $1391.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$52K
- Biotronik Inc.$16K
- E.r. Squibb & Sons, L.L.C.$7K
- Novartis$5K
- Daiichi Sankyo Inc.$1K
What the payments were for
- Consulting fees$2,0006%
- Speaking & faculty fees$14,52546%
- Grants$6,00019%
- Travel & lodging$2,1447%
- Food & beverage$6,75822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 17 | $11,370 |
| E.r. Squibb & Sons, L.L.C. | 4 | $7,248 |
| Boston Scientific | 35 | $4,775 |
| Medtronic(2 entities) | 6 | $3,255 |
| Pfizer | 8 | $2,841 |
| Abbott | 6 | $436 |
| Biosense Webster, Inc. | 3 | $313 |
| Johnson & Johnson | 2 | $250 |
| Novartis | 10 | $238 |
| Catheter Precision Inc. | 1 | $237 |
| Kestra Medical Technology Services, Inc. | 1 | $136 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $123 |
| Bardy Diagnostics, Inc. | 1 | $84 |
| Philips North America LLC | 1 | $75 |
| Amgen | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$9,997
- GENERAL - THERAPIES$3,094
- Micra$2,823
- Acticor 7 VR-T DX$529
- AMVIA EDGE$309
- EMBLEM MRI S-ICD$299
- XARELTO$250
- RESONATE EL ICD VR$248
- Carto 3$226
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$192
- Claria MRI$184
- PAMIRA$180
- TYRX$172
- BioMonitor$169
- LUX-Dx Insertable Cardiac Monitor$156
- ROTAPRO$153
- Assure WCD$136
- LUX-DX$133
- TRICLIP$117
- GENERAL PAIN MANAGEMENT$117
How this compares
$31,427 in reported general payments places this provider in the 65th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 356 | $365,572 |
| EntrestoSacubitril/Valsartan | 94 | $113,294 |
| XareltoRivaroxaban | 71 | $76,752 |
| JardianceEmpagliflozin | 11 | $18,770 |
| Dofetilide | 13 | $10,819 |
| Amiodarone Hcl | 168 | $4,154 |
| Metoprolol Succinate | 225 | $3,966 |
| Atorvastatin Calcium | 135 | $1,598 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 17 | $1,401 |
| Amlodipine Besylate | 158 | $1,015 |
| Metoprolol Tartrate | 83 | $898 |
| Flecainide Acetate | 25 | $875 |
| Losartan Potassium | 79 | $830 |
| Furosemide | 185 | $807 |
| SotalolSotalol Hcl | 36 | $773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,841 | $365,572356 claims |
| NovartisEntresto | $238 | $113,29494 claims |
| Johnson & JohnsonXarelto | $250 | $76,75271 claims |
| Boehringer IngelheimJardiance | $21 | $18,77011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Lititz
- Seth WorleyLancaster$3.7M
- John ChenaridesPittsburgh$750K
- Fermin GarciaPhiladelphia$684K
- Ralph VerdinoPhiladelphia$682K
- Pugazhendhi VijayaramanWilkes Barre$594K
- Pasquale SantangeliPhiladelphia$581K
- Joshua SilversteinPittsburgh$557K
- Francis MarchlinskiPhiladelphia$469K
- Joshua CooperPhiladelphia$405K
- Timothy MarkmanPhiladelphia$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.